Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 1, Pages 290-306Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01310
Keywords
-
Categories
Ask authors/readers for more resources
We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a flat GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole proline-valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available